Title : Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.

Pub. Date : 2020

PMID : 33194590






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The combination of Birinapant with Ralimetinib, inhibitor of p38alpha, restores the sensitivity of LKB1- and KRAS-mutated cell lines to the IAP inhibitor Birinapant. Ralimetinib serine/threonine kinase 11 Homo sapiens
2 In addition, combination of Birinapant and a KRAS pathway inhibitor, as Ralimetinib, could be useful for patients with LKB1 and KRAS-mutated NSCLC. Ralimetinib serine/threonine kinase 11 Homo sapiens